Alto Neuroscience Execs Sued Over Rosy Drug Claims

An Alto Neuroscience investor claims CEO Amit Etkin and other directors overstated the efficacy of the psychiatric biotech company's lead drug candidate for treating major depressive disorder, according to a lawsuit...

Already a subscriber? Click here to view full article